Healthcare investment grade bonds are corporate debt issued by drug makers, hospitals, insurers, medical device manufacturers, and pharmacy chains that carry credit ratings of BBB minus or higher from S&P and Fitch, or Baa3 or higher from Moody’s. The sector is unusual in fixed income: it is defensive (people get sick in any economy), durable (drug patents and FDA approvals create moats lasting 10 to 20 years), and politically exposed (Medicare drug pricing, ACA, FDA cycles). That combination has historically attracted a premium bid.
This page is the comprehensive 2026 reference for investment grade healthcare bonds. It catalogs the major issuers across seven subsectors, explains why each subsector trades the way it does, walks through the 2026 themes shaping spreads, and bridges to the NNN real estate properties leased to many of these same companies. For the cluster anchor with cross-sector bond data, see the Investment Grade Bonds anchor page. For the same credit framework applied to NNN real estate, see the IG 180 tenant ratings database.
2026 Healthcare IG Sector Snapshot
| Metric | 2026 | Context |
|---|---|---|
| Healthcare IG OAS | ~70 to 75 bps | 5 to 15 bps tight to broader IG (~80 bps) |
| Average Healthcare IG Yield | ~5.0 to 5.3 percent | Highest carry in over a decade |
| AAA Healthcare Names | 1 (Johnson & Johnson) | One of only two AAA US corporates |
| AA / Aa Tier | 3 names | Merck, Abbott, Roche (international) |
| A Tier | ~12 names | Pfizer, Lilly, UNH, Medtronic, Stryker, others |
| BBB Tier | ~20 names | Largest tier including AbbVie, CVS, Cigna, Amgen |
| Recent Notable Action | Walgreens fell to BB+ in late 2025 | Largest IG to HY transition in healthcare in over a decade |
| 2026 New Issuance | Healthcare ~10 to 12 percent of IG issuance YTD | Lilly and Pfizer led with multi tranche deals |
2026 approximations. OAS sourced from ICE BofA Healthcare US Corporate Index relative to BAMLC0A0CM (broad IG OAS). Yields are representative 10 year senior unsecured. Issuance counts from Bloomberg league tables. Not investment advice.
Why Healthcare IG Bonds Trade the Way They Do
Three structural features dominate how the market prices healthcare credit:
Defensive cash flows. Demand for healthcare is largely insensitive to recessions. Surgeries, prescriptions, and physician visits hold up through downturns. That defensive character means healthcare IG spreads typically widen less than the broader market during stress and tighten less during rallies. The sector is a stabilizer in IG portfolios.
Patent and FDA moats. A drug company with a patented blockbuster has 7 to 12 years of effectively guaranteed cash flow. A medical device with FDA approval can take 5 to 10 years for a competitor to match. These regulatory moats translate into bond markets as durable revenue stability that supports investment grade ratings even at high leverage. AbbVie carrying high BBB+ debt against Humira and Skyrizi is the textbook example.
Political exposure. Healthcare cash flows depend on government policy more than any other sector except utilities. Medicare drug price negotiation, ACA subsidies, FDA cycles, and 340B pricing all flow directly to corporate revenue. The Inflation Reduction Act drug price negotiation provisions that took effect January 2026 are the most consequential policy change in IG healthcare in 20 years. The market has priced this risk asymmetrically: pharma names with concentration in Medicare Part D drugs trade slightly wider than peers with broader revenue diversification.
2026 Themes Shaping Healthcare IG Spreads
1. The GLP-1 Refinancing Wave
Eli Lilly and Novo Nordisk are spending unprecedented capital to expand GLP-1 manufacturing for Mounjaro, Zepbound, Ozempic, and Wegovy. Lilly issued multi tranche deals in 2024 and 2025 to lock in long dated capacity. The bond market views these issuers as credit improvers despite the leverage, because GLP-1 revenue trajectories support the new debt. Lilly trades inside Pfizer at the same A1 rating because the market sees Lilly as the strongest growth story in big pharma.
2. Inflation Reduction Act Drug Pricing
The Medicare Drug Price Negotiation Program took effect January 2026 for the first 10 selected drugs. Negotiated prices represent 22 to 66 percent reductions from prior Medicare net prices. Direct revenue impacts hit Bristol-Myers Squibb (Eliquis), Merck (Januvia), Boehringer Ingelheim and Lilly (Jardiance), Johnson & Johnson (Xarelto, Imbruvica), Novo Nordisk (Fiasp/NovoLog/Tresiba insulins), AstraZeneca (Farxiga). 15 additional drugs were selected for 2027 negotiations. The credit impact is muted at the AAA/AA tier (J&J, Merck) where revenue diversification absorbs the hit, but more material at lower tiers where concentration risk shows up.
3. The Walgreens Exit From IG
Walgreens Boots Alliance lost investment grade status in October 2025 (S&P to BB+, Moody’s to Ba2) following deteriorating store level economics, Sycamore Partners private acquisition discussions, and 1,200+ store closures. This is the largest IG to HY transition in healthcare in over a decade. Walgreens NNN cap rates widened materially, while CVS NNN cap rates compressed slightly as the only investment grade pharmacy alternative. For NNN investors, Walgreens is now an HY trade with HY economics; CVS is the IG pharmacy benchmark.
4. Hospital Wage Pressure Normalizing
Post COVID nurse staffing premiums and contract labor costs that crushed hospital margins in 2022 to 2023 have normalized. HCA Healthcare, Universal Health Services, and Tenet (HY) all reported margin recovery through 2024 and 2025. Hospital IG spreads narrowed by 30 to 50 bps over 2025. The remaining concerns are Medicaid expansion uncertainty under the new Congress and ongoing 340B legal cases.
5. AI in Drug Discovery and Diagnostics
Pharma companies are deploying AI for target identification, clinical trial design, and manufacturing optimization. The capex shows up in higher cash R&D, but management teams point to improved R&D productivity as justification. Diagnostics names like Thermo Fisher, Danaher, and Agilent benefit from AI driven research demand. The bond market has been patient with the spending given the tier of credit involved.
6. Biotech Investment Grade Quality Improvement
Several biotechs have crossed firmly into investment grade over the past three years through revenue scale and balance sheet discipline. Vertex (cystic fibrosis franchise plus Casgevy gene therapy launch), Regeneron (Eylea, Dupixent), and Gilead (HIV plus oncology pipeline) now trade at solid BBB+ to A- spreads. Amgen sits one notch lower at BBB+ following the Horizon Therapeutics acquisition leverage but is on a deleveraging trajectory.
The Healthcare IG Issuer Universe
The tables below catalog the major investment grade healthcare bond issuers by subsector. Each entry shows the S&P and Moody’s rating, an approximate 2026 senior unsecured 10 year yield, and a flag indicating whether the company also appears as an NNN real estate tenant in our IG 180 database. NNN crossover names are linked through to the corresponding tenant credit rating page.
Big Pharma
Pharmaceutical manufacturers with multi billion dollar drug portfolios and long patent runways. The top tier commands the lowest yields in healthcare because of revenue diversification, defensive demand, and long patent moats.
| Issuer | Ticker | S&P | Moody’s | ~10Y Yield | NNN Tenant? |
|---|---|---|---|---|---|
| Johnson & Johnson | JNJ | AAA | Aaa | ~4.85% | No |
| Merck & Co. | MRK | A+ | Aa3 | ~4.95% | No |
| Roche Holding (Swiss issuer, USD bonds) | ROG | AA | Aa3 | ~4.90% | No |
| Novartis (Swiss issuer, USD bonds) | NVS | AA– | A1 | ~4.95% | No |
| Pfizer | PFE | A+ | A1 | ~5.00% | No |
| Eli Lilly | LLY | A+ | A1 | ~5.00% | No |
| Bristol-Myers Squibb | BMY | A | A2 | ~5.05% | No |
| AstraZeneca (UK issuer, USD bonds) | AZN | A | A2 | ~5.05% | No |
| GSK (UK issuer, USD bonds) | GSK | A | A2 | ~5.10% | No |
| Sanofi (French issuer, USD bonds) | SNY | AA | A1 | ~4.95% | No |
| Novo Nordisk (Danish issuer, USD bonds) | NVO | AA– | Aa3 | ~4.95% | No |
| AbbVie | ABBV | BBB+ | Baa1 | ~5.20% | No |
Biotech (Investment Grade Only)
Biotechs that have grown beyond clinical stage into commercial scale with sustainable revenue. The IG biotech list is short because most biotechs remain pre-revenue or sub-IG; the names below have demonstrated sustained earnings power.
| Issuer | Ticker | S&P | Moody’s | ~10Y Yield | Key Franchise |
|---|---|---|---|---|---|
| Amgen | AMGN | BBB+ | Baa1 | ~5.20% | Enbrel, Prolia, Repatha, Tezspire |
| Gilead Sciences | GILD | A– | A3 | ~5.10% | HIV franchise, oncology pipeline |
| Vertex Pharmaceuticals | VRTX | BBB+ | Baa1 | ~5.20% | Cystic fibrosis, Casgevy gene therapy |
| Regeneron Pharmaceuticals | REGN | BBB+ | Baa1 | ~5.20% | Eylea, Dupixent (with Sanofi) |
| Biogen | BIIB | BBB | Baa2 | ~5.30% | MS franchise, Alzheimer’s pipeline |
Medical Devices and Tools
Manufacturers of implantable devices, surgical equipment, diagnostic instruments, and life sciences tools. This subsector has been a steady IG performer with consistent ratings stability.
| Issuer | Ticker | S&P | Moody’s | ~10Y Yield | Subspecialty |
|---|---|---|---|---|---|
| Abbott Laboratories | ABT | AA– | Aa3 | ~4.95% | Diagnostics, devices, nutrition |
| Medtronic | MDT | A | A2 | ~5.05% | Cardiac, neuro, surgical |
| Stryker | SYK | A | A2 | ~5.05% | Orthopedics, surgical |
| Becton Dickinson (BD) | BDX | BBB | Baa2 | ~5.30% | Medical supplies, diagnostics |
| Boston Scientific | BSX | BBB+ | Baa1 | ~5.20% | Cardiovascular, electrophysiology |
| Edwards Lifesciences | EW | BBB+ | Baa1 | ~5.20% | Heart valves (TAVR) |
| Zimmer Biomet | ZBH | BBB | Baa3 | ~5.35% | Orthopedics |
| Baxter International | BAX | BBB | Baa2 | ~5.30% | Renal, hospital products |
| Thermo Fisher Scientific | TMO | A– | Baa1 | ~5.10% | Life sciences tools, diagnostics |
| Danaher | DHR | A– | Baa1 | ~5.10% | Bioprocessing, diagnostics |
| Agilent Technologies | A | A | A2 | ~5.05% | Analytical instruments |
| Waters Corporation | WAT | BBB+ | Baa2 | ~5.20% | Mass spectrometry, chromatography |
| Illumina | ILMN | BBB | Baa3 | ~5.40% | Genomic sequencing |
Health Insurers and Managed Care
Companies providing health insurance, pharmacy benefit management, and integrated care. Recent vertical integration (UnitedHealth/Optum, CVS/Aetna, Cigna/Express Scripts) has reshaped the sector’s credit profiles toward larger, more diversified revenue bases.
| Issuer | Ticker | S&P | Moody’s | ~10Y Yield | NNN Tenant? |
|---|---|---|---|---|---|
| UnitedHealth Group | UNH | A+ | A2 | ~5.00% | Indirect (Optum/Concentra) |
| Elevance Health | ELV | A | A2 | ~5.05% | No |
| Cigna | CI | A– | Baa1 | ~5.10% | No |
| CVS Health | CVS | BBB | Baa2 | ~5.30% | Yes CVS Bonds vs NNN → |
| Humana | HUM | BBB+ | Baa3 | ~5.30% | No |
| Centene | CNC | BBB– | Baa3 | ~5.45% | No |
Pharmacy and Drug Distribution
Retail pharmacies and the wholesale distribution chain that moves drugs from manufacturers to dispensaries. The retail pharmacy half of this subsector has been under credit pressure; the distribution half remains stable.
| Issuer | Ticker | S&P | Moody’s | ~10Y Yield | NNN Tenant? |
|---|---|---|---|---|---|
| CVS Health (Pharmacy) | CVS | BBB | Baa2 | ~5.30% | Yes View comparison → |
| Walgreens Boots Alliance | WBA | BB+ (HY) | Ba2 (HY) | ~6.8 to 7.5% | Yes (NNN repriced wider as HY) |
| McKesson | MCK | A– | Baa1 | ~5.10% | No |
| Cencora (formerly AmerisourceBergen) | COR | A– | Baa1 | ~5.10% | No |
| Cardinal Health | CAH | BBB+ | Baa3 | ~5.30% | No |
Hospitals and Healthcare Services
For profit hospital operators and outpatient services. This subsector includes some sub-investment grade names (HCA at Moody’s Ba1, DaVita BB+) that nonetheless trade close to IG levels because of stable cash flows, and some IG names with thin margin profiles.
| Issuer | Ticker | S&P | Moody’s | ~10Y Yield | NNN Tenant? |
|---|---|---|---|---|---|
| HCA Healthcare | HCA | BBB– | Ba1 (HY) | ~5.6 to 5.9% | Yes |
| Universal Health Services | UHS | BBB– | Baa3 | ~5.45% | Limited NNN exposure |
| DaVita (HY but proximate to IG) | DVA | BB+ (HY) | Ba1 (HY) | ~6.5 to 7.1% | Yes (dialysis NNN) |
| Fresenius Medical Care | FMS | BBB– | Baa3 | ~5.45% | Yes (dialysis NNN) |
| Encompass Health | EHC | BB+ (HY) | Ba2 (HY) | ~6.5 to 7.0% | Limited NNN exposure |
Diagnostics and Lab Services
Clinical labs and diagnostic service providers. These names appear in NNN portfolios via standalone lab buildings and clinical office leases.
| Issuer | Ticker | S&P | Moody’s | ~10Y Yield | NNN Tenant? |
|---|---|---|---|---|---|
| Laboratory Corp of America (Labcorp) | LH | BBB+ | Baa2 | ~5.20% | Yes |
| Quest Diagnostics | DGX | BBB+ | Baa2 | ~5.20% | Yes |
Healthcare NNN Crossover
Healthcare bond issuers that also appear as NNN real estate tenants in our IG 180 database. These crossover names are unique because the same corporate credit backs both the bond payment and the lease payment, allowing investors to evaluate the same credit risk through two different yield instruments.
| Tenant | Bond Rating | Bond Yield | NNN Cap Rate | Bond vs NNN Page |
|---|---|---|---|---|
| CVS Health | BBB / Baa2 | ~5.30% | 6.0 to 7.5% | CVS Bonds vs NNN → |
| Walgreens | BB+ / Ba2 (now HY) | ~6.8 to 7.5% | 7.0 to 8.5% | HY analysis (no IG comparison page) |
| DaVita | BB+ / Ba1 (HY) | ~6.5 to 7.1% | 6.0 to 7.5% | HY proximate; trades like BBB minus |
| Fresenius Medical Care | BBB / Baa3 | ~5.45% | 5.5 to 7.25% | Bond vs NNN page pending |
| HCA Healthcare | BBB / Ba1 | ~5.6 to 5.9% | 5.5 to 7.25% | Bond vs NNN page pending |
| LabCorp | BBB+ / Baa2 | ~5.20% | 5.5 to 7.0% | Bond vs NNN page pending |
| Quest Diagnostics | BBB+ / Baa2 | ~5.20% | 5.5 to 7.0% | Bond vs NNN page pending |
Several additional healthcare NNN tenants in the IG 180 database are private equity owned and do not issue public bonds. These include Aspen Dental, Heartland Dental, Pacific Dental Services, MyEyeDr, Concentra Urgent Care, Banfield Pet Hospital, and Octapharma Plasma. For these names, NNN underwriting relies on private equity sponsor strength, store level economics, and lease guarantor structure rather than public credit ratings.
Sector-Specific Risks for Healthcare IG Bonds
Patent cliff risk. Pharma issuer revenue is concentrated in a handful of branded drugs. When a top selling drug loses patent protection (the –cliff–), revenue can fall 60 to 90 percent in 18 months as generics enter. AbbVie’s Humira cliff in 2023 was the textbook example. Pfizer faces a sequence of cliffs through 2028. Underwriting healthcare IG requires understanding each issuer’s cliff exposure and pipeline replacement.
Drug pricing legislation. Beyond the IRA, ongoing legislative threats include direct Medicare price controls on Part B drugs, international reference pricing, and 340B program changes. The political risk premium embedded in pharma spreads is real but historically over compensated; pharma has outperformed broad IG over multiple Congressional cycles.
FDA cycles. FDA approval and rejection decisions move spreads in real time. Companies with binary regulatory events trade with elevated spread volatility around PDUFA dates. The 2026 FDA agenda includes high profile decisions on next generation oncology, gene therapies, and biosimilar pathways.
Tariff and supply chain. Roughly 80 percent of US generic API supply originates in China and India. Tariff escalation directly hits generic margins and indirectly raises costs for branded manufacturers using offshore supply. Pfizer, Lilly, and Merck have invested in domestic manufacturing partly in anticipation of tariff risk.
Litigation tail risk. Opioid litigation, talc class actions (J&J), 3M earplug, and PFAS exposure create reserve volatility that occasionally surfaces in spread widening. The market has generally been good at pricing these tails into spreads in advance.
Hospital margin sensitivity. Hospital operators (HCA, UHS) are leveraged to wage trends, payer mix, and Medicaid policy. Margins moved meaningfully in 2022 to 2023 and recovered in 2024 to 2025. Future Medicaid expansion or contraction would move spreads on this group.
Recent Rating Actions
- Walgreens Boots Alliance: Downgraded to BB+ (S&P) and Ba2 (Moody’s) in October 2025 following Sycamore Partners acquisition discussions and continued store closure program. Largest fallen angel in healthcare in over a decade.
- Cigna: S&P upgraded to A– from BBB+ in late 2025 reflecting improved leverage post Express Scripts integration and stable Evernorth growth.
- Eli Lilly: Multiple multi tranche issuances through 2025 absorbed by the market at tight spreads despite increased leverage, reflecting the GLP-1 growth thesis. Ratings unchanged at A+ / A1.
- Johnson & Johnson: Affirmed at AAA / Aaa following Kenvue spinoff completion. One of only two AAA US corporates remaining.
- Centene: Stable BBB outlook maintained despite ongoing Medicaid redetermination headwinds and 2024 cyber incident remediation.
- HCA Healthcare: Outlook revised to positive (S&P) reflecting margin recovery and disciplined capital allocation. Moody’s remains Ba1 with potential upgrade momentum.
Frequently Asked Questions
Healthcare IG bonds yield approximately 5.0 to 5.3 percent for representative 10 year senior unsecured paper, with the AAA tier (Johnson & Johnson) at the low end (~4.85%) and lower BBB tier names like Centene and Humana at the high end (~5.45%). The sector trades 5 to 15 basis points tight to the broader IG corporate index in normal markets.
Healthcare bonds are generally considered defensive within IG corporates because demand is largely insensitive to economic cycles. Default rates in the IG healthcare segment have been low historically. The sector’s primary risks are patent cliffs (specific to pharma), drug pricing legislation, and FDA regulatory cycles rather than economic cycle exposure. For comparison with the broader IG default record, see our analysis of Investment Grade vs Non Investment Grade Bonds.
The IRA Medicare Drug Price Negotiation Program took effect January 2026 with the first 10 selected drugs subject to negotiated prices 22 to 66 percent below prior Medicare net prices. The credit impact varies by issuer concentration: AAA/AA tier names (J&J, Merck) have absorbed the impact through revenue diversification, while lower BBB tier names with concentration in negotiated drugs trade slightly wider. The market has been pricing IRA risk for several years; the actual spread impact at implementation has been modest.
Major crossover names include CVS Health (BBB), Walgreens (now HY at BB+/Ba2 since October 2025), DaVita (HY but trades close to IG), Fresenius Medical Care (BBB), HCA Healthcare (BBB/Ba1), LabCorp (BBB+), and Quest Diagnostics (BBB+). UnitedHealth has indirect exposure through its Optum/Concentra urgent care subsidiary. Each crossover relationship lets investors compare the bond yield to the NNN cap rate on the same credit. See the Bond to NNN Spread anchor page for the full methodology.
Walgreens Boots Alliance was downgraded to BB+ (S&P) and Ba2 (Moody’s) in October 2025 following deteriorating store level economics, an extended store closure program (1,200+ stores), and acquisition negotiations with Sycamore Partners. The credit profile reflects sustained operating losses, declining pharmacy reimbursement margins, and a balance sheet that no longer supports investment grade metrics. CVS remains the only investment grade pharmacy chain, and CVS NNN cap rates have compressed slightly as a result of being the sole IG alternative.
Healthcare REIT bonds (Welltower, Ventas, Healthpeak, Medical Properties Trust) are issued by real estate companies that own healthcare facilities and lease them to operators. The credit risk is real estate plus operator concentration, not pharmaceutical or device company performance. Healthcare REIT bonds typically yield 25 to 75 basis points higher than healthcare corporate bonds at the same rating tier, reflecting the real estate illiquidity premium and operator credit risk pass through.
Healthcare corporate bond coupon income is taxed as ordinary income at the federal level (up to 37 percent), plus state income tax and the 3.8 percent Net Investment Income Tax for high earners. This is the same as any other corporate bond. NNN real estate leased to the same healthcare credits offers structurally different tax treatment through depreciation deductions and 1031 exchange eligibility. See the Bond to NNN comparison for after tax math.
Healthcare NNN or Capital Markets?
InvestmentGrade.com represents buyers and sellers of healthcare NNN real estate (CVS, Walgreens, DaVita, dialysis, dental, urgent care, plasma, veterinary) and arranges debt for healthcare CRE owners. On the majority of NNN transactions, the listing broker pays a cooperating commission, so there is typically no separate fee to you as the buyer for professional representation.
Find It — On market and off market healthcare NNN sourced and underwritten for your criteria.
Fund It — 150+ lender relationships covering healthcare CRE acquisition, refinance, and recapitalization.
Exit It — Healthcare NNN buyer pool is deep across 1031 exchange, family office, and institutional capital.
Exchange It — 1031 exchange into or out of healthcare NNN with deadline driven execution.
Educational content only. InvestmentGrade.com is a commercial real estate brokerage and educational publisher. We do not sell, broker, underwrite, or solicit any bonds, securities, or investment products. Yields, ratings, and prices referenced are approximate, fluctuate continuously, and are sourced from public market data as of 2026. Nothing on this page constitutes investment advice, an offer to sell, or a solicitation to buy any security. Consult a licensed broker-dealer, registered investment advisor, or tax professional before making any investment decision. For SEC investor education, visit investor.gov.
